Fig. 2: CCHFV-M10200 DNA vaccination elicits CCHFV-IbAr 10200 specific antibodies. | npj Vaccines

Fig. 2: CCHFV-M10200 DNA vaccination elicits CCHFV-IbAr 10200 specific antibodies.

From: A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice

Fig. 2

Groups of 10 female C57BL/6 mice were vaccinated with 50 μg CCHFV-M10200 or empty vector on days 0, 21, and 42 by IM-EP. a CCHFV-IbAr 10200-specific antibody responses were analyzed 21 days post third vaccination for ELISA endpoint titers. Mice that succumbed to challenge are highlighted red. b Temporal anti-CCHFV-IbAr 10200 IgG responses in vaccinated mice. The arrows indicate DNA vaccination time points. Data are the group mean averages ± SD. ***p < 0.001. The endpoint titer p value was determined by Student’s t test with a 95% confidence interval.

Back to article page